How do we find the top stock of 2020? The best performers in 2019 offer some clues.
A host of major healthcare companies and drug retailers are collaborating on a system to combat fake drugs.
A recent acquisition and a new product launch held back earnings, but should be beneficial over the long term.
These young companies have already delivered big returns for their shareholders, and there's every reason to expect more to come.
Antibody-based treatments can be used both to protect people from infection and to treat those already affected.
The company is advancing a new treatment for people with Alexander disease.
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
Shares of the genetic disease specialist were essentially flat in late afternoon trading.
The medical device maker's stock dropped 9%, then recovered.
An insurance-shopping portal, a U.K. software company, and a Brazilian medical school operator all have potential for outsize returns.
The volatile biotech has been up and down since its massive gain back in November.
These two biotechs have major drugs that should be hitting the market soon.
The Singapore internet giant might be entering the banking business.
The two companies hope to decode the human immune system.
Around 99% of cases are in China.
The drug candidate is in phase 3 trials as a treatment of myelodysplastic syndrome (MDS), which often leads to blood and bone marrow cancers.
Right now you can buy an interstellar airline, a vaccine specialist, and an oil tanker company -- all on sale.
Federal regulations are stifling the industry, and one company is taking advantage.
First FDA-approved medicine for thyroid eye disease.
The tech giant wants to bring artificial intelligence to bear on solving diseases like cancer, but the side effect of that could be a loss of our privacy.